DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

Information source: University of Utah
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Drug Interactions; Pharmacokinetics

Intervention: Daptomycin (Drug); Rifampin (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: University of Utah

Official(s) and/or principal investigator(s):
Russell Benefield, Pharm.D., Principal Investigator, Affiliation: University of Utah


The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body. In addition, the effect of polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the body) on the blood levels of daptomycin will be evaluated. The hypotheses are that rifampin will decrease the blood levels of daptomycin and that the effect will be greater for certain P-glycoprotein polymorphisms.

Clinical Details

Official title: Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Daptomycin total, renal, and non-renal clearance

Daptomycin Volume of Distribution

Daptomycin Elimination Rate Constant

Daptomycin Free and Total Peak Concentrations

Daptomycin Free and Total 24 hour Concentrations

Daptomycin Free and Total Area Under the Concentration-Time Curve (AUC) from 0 to 24 hours

Daptomycin Free and Total AUC from 0 to Infinity

Percent Protein Binding of Daptomycin

Secondary outcome:

P-glycoprotein Polymorphism

Number of Participants with Adverse Events

Detailed description: This will be an open-label, sequential pharmacokinetic study in 12 healthy volunteers. After providing informed consent, participants meeting inclusion criteria will be administered daptomycin 6 mg/kg over 2 minutes and blood and urine samples will be collected over a 24 hour period after infusion. Following this, participants will be given a 13 day supply of rifampin 600 mg/day to be taken at home. After completion of the rifampin course, a second pharmacokinetic sampling will be performed (day 15 overall). Participants will be administered a dose of rifampin 600 mg then once again be administered daptomycin 6 mg/kg over 2 minutes and blood and urine samples will be collected over a second 24 hour period. A blood sample will be obtained at the first study visit for determination of each participant's P-glycoprotein genotype.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Ability to provide informed consent

- If female of child bearing potential, on reliable method of contraception and

negative pregnancy test at enrollment Exclusion Criteria:

- Obesity (body mass index > 30)

- Creatinine clearance < 80 ml/min

- Creatine phosphokinase > 2 times upper limit of normal at enrollment

- Aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase > 3

times upper limit of normal at enrollment

- History of liver disease or cirrhosis

- History of congestive heart failure

- Allergy or intolerance to rifampin or daptomycin

- Need for concomitant non-study medications during the study period

- Inability to abstain from grapefruit juice or herbal supplements (such as St. John's

wort) during the study period

- Receipt of study drugs within 30 days prior to enrollment

- Pregnancy or lactation

- Inability to adhere to study procedures

Locations and Contacts

University of Utah, Salt Lake City, Utah 84132, United States
Additional Information

Starting date: May 2014
Last updated: May 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017